Ultratrace iobenguane I 131

DRUG2 trials

Sponsors

Molecular Insight Pharmaceuticals, Inc.

Conditions

CarcinoidNeuroblastomaParagangliomaPheochromocytoma

Phase 1

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

CompletedNCT00339131

Molecular Insight Pharmaceuticals, Inc.Carcinoid, Paraganglioma, Pheochromocytoma

Start: 2006-06-30End: 2007-01-31Target: 24Updated: 2011-10-12

Phase 2

Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma

WithdrawnNCT00992173

Molecular Insight Pharmaceuticals, Inc.Neuroblastoma

Start: 2010-01-31Updated: 2015-11-26

Related Papers

SUN-345 Safety Analysis of High-Specific-Activity I-131 MIBG (AZEDRA®) in Patients with Iobenguane Scan Positive Cancers

Journal of the Endocrine Society2019-04-012 citations